Peanut Allergy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The peanut allergy market size is expected to increase from USD 0.56 billion in 2025 to USD 0.63 billion in 2026 and reach USD 1.14 billion by 2031, growing at a CAGR of 12.49% over 2026-2031. This report is Segmented by Therapy Class / Modality (Immunotherapy, Epinephrine, Antihistamines, and Others), Route of Administration (Oral, Injectable, and Others), Patient Age Group (Toddlers, Children & Adolescents, and Adults), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market and Forecasted in Terms of Value (USD).

Global Peanut Allergy Market Trends and Insights

Anti-IgE Biologic Approval Expands Eligible Treated Population

The approval of omalizumab for IgE-mediated food allergy in February 2024 shifted care from single-allergen desensitization toward protection against accidental exposures across multiple foods, which aligns with day-to-day risk management for families who juggle several co-allergies. Pivotal OUTMATCH data showed that 68% of treated participants tolerated at least 600 mg of peanut protein without moderate-to-severe symptoms compared with 5% on placebo, while demonstrating concurrent gains for milk, egg, and cashew at thresholds relevant to real-world exposures, which reframed discussions about comprehensive protection versus single-allergen desensitization. Stage 2 results released in March 2025 reported no serious adverse events in patients receiving omalizumab monotherapy, compared with higher event rates in oral immunotherapy, and lower epinephrine use among omalizumab-treated patients, which reinforced the appeal of a safety-first strategy for families wary of frequent reactions during dose escalation.

The ability to protect across allergens at dosing intervals every 2 to 4 weeks can attract patients who previously avoided therapy due to daily dosing demands and lifestyle disruptions, broadening practical eligibility. The clinical profile sets a new baseline for shared decision-making by allowing families to pursue meaningful protection without navigating daily reaction risk inherent in oral protocols. As more centers integrate biologics into pathways, the peanut allergy market is expected to capture patients who value steady-state safety over maximal desensitization.

Toddler Expansion in OIT Indications Accelerates Earlier Initiation and Uptake

The July 2024 extension of Palforzia’s indication to ages 1 to 3 leveraged immune plasticity in very young children, which supports higher tolerance thresholds and improved safety signals during supervised escalation in eligible toddlers. The POSEIDON trial reported that 61.2% of treated toddlers tolerated 2,000 mg of peanut protein at exit challenge compared with 2.1% on placebo, and noted immunologic signals consistent with blunting of sensitization trajectories when started early, which supports a front-loaded approach to care for newly diagnosed families. Access workflows remained complex under REMS, since each escalation step required supervised dosing at certified centers with observation, which created scheduling friction in regions with limited pediatric allergists and long appointment backlogs.

Accessibility varied by state, and multiple regions lacked fellowship training programs to replenish the pipeline, which constrained scaling during the indication’s early window. The January 2026 discontinuation decision, with final availability through July 31, 2026, disrupted continuity for existing patients and paused new starts, which shifted focus to non-oral modalities that can operate outside REMS while maintaining pediatric tolerability advantages. This sequence preserves the clinical rationale for early intervention while redirecting operational momentum toward modalities that fit within practice capacity.

Boxed Warnings, Anaphylaxis Risk, and EoE Concerns Constrain OIT Adoption

Oral immunotherapy raises thresholds through repeated exposure, which also raises the risk of treatment-related reactions during escalation and maintenance, and this tradeoff requires extensive counseling and careful monitoring. Clinical experience and society guidance emphasize the possibility of eosinophilic esophagitis and the need to interrupt therapy if symptoms emerge, which adds procedural steps and specialist involvement that many community practices find hard to sustain at scale. Lifestyle constraints attached to dosing, including activity modifications after administration and strict adherence to protocols during illness, reduce day-to-day flexibility for families. Practices also face documentation and medicolegal overhead whenever severe reactions occur, which nudges smaller centers to limit offerings or refer to academic hubs that maintain robust escalation infrastructure. The REMS framework around standardized oral peanut products aimed to reduce risk, but it also introduced center certification, monitoring, and inventory management steps that increased operational friction. Over time, this set of clinical and operational considerations has directed some families and clinicians toward modalities with lower systemic reaction risk, which influences patient flow within the peanut allergy market.

Other drivers and restraints analyzed in the detailed report include:

• Non-Oral Modalities (EPIT, SLIT) Progress Toward Approval With Favorable Tolerability
• At-home/Self-Injection Pathways Reduce Visit Burden and Improve Persistence
• Coverage Variability and Delistings Hinder Access and Continuity

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Immunotherapy’s 15.63% CAGR signals a durable shift toward preventive care, even as epinephrine retained 43.16% share in 2025, given its role in anaphylaxis rescue. Epicutaneous immunotherapy posted favorable Phase 3 results in children, with a 46.6% responder rate and few treatment-related severe events, which makes it attractive for families that want threshold gains with lower systemic reaction risk. Omalizumab’s approval for IgE-mediated food allergy added an option for cross-allergen protection at regular intervals, which supports families that prioritize safety and fewer clinic events during maintenance. Oral immunotherapy achieves higher desensitization for some patients but requires daily adherence and tolerance for more frequent reactions, which narrows the pool of families willing to initiate or persist.

As standardized oral peanut immunotherapy exits the market in mid-2026, practices are planning transition pathways that emphasize patches or biologics for eligible patients, which could expand treated volume through better alignment with caregiver risk tolerance. Rescue and supportive medications remain foundational but do not modify disease, which caps their contribution to long-run threshold changes. As a result, the peanut allergy market is reallocating growth toward modalities that reduce day-to-day exposure risk, with multiple age-tailored options. The evidence base for EPIT and biologics will continue to mature, and both modalities pair with family-centered tradeoffs that are easier to accept than daily oral dosing for many households. Immunotherapy’s trajectory remains strongest in pediatric cohorts, and ongoing regulatory interactions for patch-based products and real-world registry experience for biologics are expected to deepen adoption patterns in centers that balance safety, practicality, and clinical thresholds. During this transition, clinician workflow and payer policy will remain the main governors of pace. Where practices can stand up efficient protocols and achieve predictable coverage windows, initiation rates tend to improve. Where authorization and site capacity remain tight, practices keep families on robust rescue plans while evaluating preventive fit. This dynamic keeps both tracks relevant, but the direction of growth within the peanut allergy market favors preventive care.

Complete Report Scope:

• By Therapy Class / Modality
  • Immunotherapy
  • Epinephrine
  • Antihistamines
  • Others
• By Route of Administration
  • Oral
  • Injectable
  • Others
• By Patient Age Group
  • Toddlers
  • Children & Adolescents
  • Adults
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 36.53% of the 2025 market value. Dense specialty networks and reimbursement pathways that can accommodate high-cost preventive therapies support early adoption, while payer steps can still slow starts when prior authorization is complex. Workforce capacity remains a flashpoint, and national societies continue to advocate for more graduate medical education slots to close access gaps in underserved states. Canada’s public coverage model supports equitable goals, yet provincial formularies evaluate new products cautiously and can delay funded access until more outcome and budget impact data is assembled. In this context, biologics and emerging patches should gain share where centers harmonize scheduling, monitoring, and authorization steps into reliable flows. The peanut allergy market will continue to expand as practice models standardize and payer pathways stabilize.

Asia-Pacific is projected to be the fastest-growing region at a 16.57% CAGR through 2031, driven by urbanization-linked exposure patterns, rising diagnoses, and expanding specialist training. In China, published work highlights meaningful peanut sensitization among children in metropolitan areas but also documents capacity limits in specialty care, which complicates access to gold-standard oral food challenges and narrows real-world treatment pathways. Emergency readiness varies across the region, and published analyses show low rates of pre-hospital epinephrine in specific locales, which underscores the role of caregiver training and device availability in outcomes. Japan presents a distinct pattern where risk-averse prescribing culture and daily dosing aversion have tempered oral immunotherapy uptake despite documented sensitization in very young children, which may shift gradually as non-oral modalities grow their evidence base. Southeast Asian health systems have been active in anaphylaxis education, and clinical settings that equip caregivers with reliable rescue plans are laying groundwork for preventive pathways. As authorized preventive options expand, the peanut allergy market should accelerate in urban hubs with strong pediatric focus and growing middle-class demand.

Europe combines mature allergy infrastructure in Germany, the UK, and France with uneven commissioning for standardized oral products and variable capacity for follow-up escalation visits. The January 2026 decision to discontinue standardized oral peanut immunotherapy affected families mid-treatment and reversed momentum in centers that had built small pipelines, which pushed attention toward non-oral preventive alternatives and biologic protection. Southern Europe retains more conservative treatment patterns, with gradual adoption of preventive modalities as coverage pathways and clinic workflows evolve. Central and Eastern Europe are still scaling specialty capacity and reimbursement frameworks that could support structured escalation visits and monitoring. The Middle East and Africa display concentrated demand in Gulf economies that import advanced therapeutics and lean on expatriate-driven specialty services, while many sub-Saharan markets are earlier in the readiness curve due to competing health priorities. South American growth is strongest in major urban centers with private specialty networks, where awareness is rising among middle-income families. Collectively, these dynamics support steady regional expansion of the peanut allergy market as modalities map onto local coverage, capacity, and caregiver preferences.

List of Companies Covered in this Report:

• Aimmune Therapeutics, Inc.
• ALK-Abelló
• Alladapt Immunotherapeutics, Inc.
• Camallergy Ltd
• COUR Pharmaceuticals Development Company, Inc.
• DBV Technologies S.A.
• F. Hoffmann‑La Roche Ltd
• Greer Laboratories, Inc.
• IgGenix, Inc.
• Intrommune Therapeutics, Inc.
• Novartis
• Prota Therapeutics Pty Ltd
• Regeneron Pharmaceuticals
• Sanofi

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support